News
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that data from the Phase III ...
Stocktwits on MSN2d
IO Biotech Stock Slumps After Trial Of Cancer Therapy Plus Keytruda Misses Study Goal: Retail Sees Shares Rise 10x
IO Biotech (IOBT) announced on Monday that its investigational and therapeutic cancer vaccine, Cylembio, in combination with ...
NRG Oncology recently reported the results of the phase II/III NRG-BN007 clinical trial showing that combining ipilimumab and ...
The FDA accepted vepdegestrant’s new drug application for ER+/HER2–, ESR1-mutated advanced breast cancer with a June 5, 2026, ...
Cylembio is a therapeutic cancer vaccine candidate that targets cells and immune-suppressive cells in the tumor microenvironment through activation and expansion of T cells against IDO1 and/or PD-L1 ...
NRG Oncology recently reported the results of the National Cancer Institute sponsored phase II/III NRG-BN007 clinical trial showing that combining ipilimumab and nivolumab with radiation therapy (RT) ...
Medpage Today on MSN5d
KRAS Inhibitor Reduces Progression Risk in Pretreated Lung Cancer
The objective response rate (ORR) was 32% with adagrasib versus 9% with docetaxel (OR 4.68, 95% CI 2.56-8.56, P <0.0001), ...
16hon MSN
Revolution Medicines Receives FDA Breakthrough Therapy Designation for Elironrasib for Lung Cancer
Revolution Medicines Inc. (NASDAQ: RVMD) is one of the best upside stocks to invest in now. Earlier on July 23, Revolution ...
IO Biotech’s cancer vaccine has “narrowly” failed to beat Merck's blockbuster oncology drug Keytruda in a phase 3 melanoma ...
New research reveals that combining talazoparib with enzalutamide significantly enhances survival rates in metastatic ...
Compass Therapeutics (CMPX) stock sees 21% surge after its Q2 2025 financials included positive trial updates on its cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback